With over 30 years’ experience as a litigator, Karla Palmer’s focus at Hyman Phelps is representation of drug compounders, both in the FDCA Section 503A and 503B spaces. She handles matters related to FDA and state board inspections, Form 483 and Warning Letter including CGMP and USP remediation activities, investigations, regulatory meetings, board hearings, and consent decree negotiations.